Dettling M, Cascorbi I, Hellweg R, Deicke U, Weise L, Müller-Oerlinghausen B
Department of Psychiatry, Freie Universität Berlin, Germany.
Pharmacopsychiatry. 1999 May;32(3):110-2. doi: 10.1055/s-2007-979204.
Whether or not olanzapine causes bone marrow toxicity is still a matter of debate. In spite of pre-marketing and post-marketing clinical trials, and although there have been no cases in animals of olanzapine-induced neutropenia or agranulocytosis, the risk of bone marrow toxicity cannot be excluded. The present paper addresses the following questions: what is the potential background of drug-induced agranulocytosis? Are there any case reports supporting the view that olanzapine has relevant bone marrow toxicity? What strategies might be helpful in identifying the pathological mechanisms underlying this side effect?
奥氮平是否会导致骨髓毒性仍是一个有争议的问题。尽管有上市前和上市后的临床试验，而且在动物中尚无奥氮平诱发中性粒细胞减少或粒细胞缺乏症的病例，但骨髓毒性的风险仍不能排除。本文探讨以下问题：药物性粒细胞缺乏症的潜在背景是什么？是否有病例报告支持奥氮平具有相关骨髓毒性的观点？哪些策略可能有助于确定这种副作用的病理机制？
